Literature DB >> 26997361

Indigenous Australians with non-small cell lung cancer or cervical cancer receive suboptimal treatment.

Lisa J Whop1, Christina M Bernardes1,2, Srinivas Kondalsamy-Chennakesavan3, Deepak Darshan3,4, Naven Chetty5, Suzanne P Moore1, Gail Garvey1, Euan Walpole6, Peter Baade7, Patricia C Valery1,2.   

Abstract

BACKGROUND: Lung cancer and cervical cancer are higher in incidence for Indigenous Australians and survival is worse compared with non-Indigenous Australians. Here we aim to determine if being Indigenous and/or other factors are associated with patients receiving "suboptimal treatment" compared to "optimal treatment" according to clinical guidelines for two cancer types.
METHODS: Data were collected from hospital medical records for Indigenous adults diagnosed with cervical cancer and non-small cell lung cancer (NSCLC) and a frequency-matched comparison group of non-Indigenous patients in the Queensland Cancer Registry between January 1998 and December 2004. The two cancer types were analyzed separately.
RESULTS: A total of 105 women with cervical cancer were included in the study, 56 of whom were Indigenous. Indigenous women had higher odds of not receiving optimal treatment according to clinical guidelines (unadjusted OR 7.1; 95% CI, 1.5-33.3), even after adjusting for stage (OR 5.7; 95% CI, 1.2-27.3). Of 225 patients with NSCLC, 198 patients (56% Indigenous) had sufficient information available to be analyzed. The odds of receiving suboptimal treatment were significantly higher for Indigenous compared to non-Indigenous NSCLC patients (unadjusted OR 1.9; 95% CI, 1.0-3.6) and remained significant after adjusting for stage, comorbidity and age (adjusted OR 2.1; 95% CI, 1.1-4.1).
CONCLUSIONS: The monitoring of treatment patterns and appraisal against guidelines can provide valuable evidence of inequity in cancer treatment. We found that Indigenous people with lung cancer or cervical cancer received suboptimal treatment, reinforcing the need for urgent action to reduce the impact of these two cancer types on Indigenous people.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Indigenous Australians; cervical cancer, treatment; clinical guidelines; concordance; lung cancer

Mesh:

Year:  2016        PMID: 26997361     DOI: 10.1111/ajco.12463

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

1.  Psychological distress among Indigenous Australian cancer survivors.

Authors:  Gail Garvey; J Cunningham; M Janda; V Yf He; P C Valery
Journal:  Support Care Cancer       Date:  2017-12-14       Impact factor: 3.603

2.  Barriers to lung cancer care: health professionals' perspectives.

Authors:  J Dunn; G Garvey; P C Valery; D Ball; K M Fong; S Vinod; D L O'Connell; S K Chambers
Journal:  Support Care Cancer       Date:  2016-10-10       Impact factor: 3.603

3.  Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).

Authors:  Abbey Diaz; Peter D Baade; Patricia C Valery; Lisa J Whop; Suzanne P Moore; Joan Cunningham; Gail Garvey; Julia M L Brotherton; Dianne L O'Connell; Karen Canfell; Diana Sarfati; David Roder; Elizabeth Buckley; John R Condon
Journal:  PLoS One       Date:  2018-05-08       Impact factor: 3.240

4.  Adherence to clinical practice guidelines (CPGs) for the treatment of cancers in Australia and the factors associated with adherence: a systematic review protocol.

Authors:  Mia Bierbaum; Frances Rapport; Gaston Arnolda; Yvonne Tran; Bróna Nic Giolla Easpaig; Kristiana Ludlow; Jeffrey Braithwaite
Journal:  BMJ Open       Date:  2021-09-21       Impact factor: 2.692

5.  Cancer treatment and the risk of cancer death among Aboriginal and non-Aboriginal South Australians: analysis of a matched cohort study.

Authors:  David Banham; David Roder; Marion Eckert; Natasha J Howard; Karla Canuto; Alex Brown
Journal:  BMC Health Serv Res       Date:  2019-10-29       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.